Literature DB >> 25801567

Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.

Kanokrat Rungtivasuwan1, Anchalee Avihingsanon2, Narukjaporn Thammajaruk3, Siwaporn Mitruk4, David M Burger5, Kiat Ruxrungtham2, Baralee Punyawudho6, Thitima Pengsuparp7.   

Abstract

Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively. Genetic polymorphisms of these transporters may affect the plasma concentrations of tenofovir. Therefore, the aim of this study was to investigate the influence of genetic and nongenetic factors on tenofovir plasma concentrations. A cross-sectional study was performed in Thai HIV-infected patients aged ≥18 years who had been receiving tenofovir disoproxil fumarate at 300 mg once daily for at least 6 months. A middose tenofovir plasma concentration was obtained. Multivariate analysis was performed to investigate whether there was an association between tenofovir plasma concentrations and demographic data, including age, sex, body weight, estimated glomerular filtration rate (eGFR), hepatitis B virus coinfection, hepatitis C virus coinfection, duration of tenofovir treatment, concomitant use of ritonavir-boosted protease inhibitors, and polymorphisms of ABCC2 and ABCC4. A total of 150 Thai HIV-infected patients were included. The mean age of the patients was 43.9 ± 7.2 years. The mean tenofovir plasma concentration was 100.3 ± 52.7 ng/ml. In multivariate analysis, a low body weight, a low eGFR, the concomitant use of ritonavir-boosted protease inhibitors, and the ABCC4 4131T → G variation (genotype TG or GG) were independently associated with higher tenofovir plasma concentrations. After adjusting for weight, eGFR, and the concomitant use of ritonavir-boosted protease inhibitors, a 30% increase in the mean tenofovir plasma concentration was observed in patients having the ABCC4 4131 TG or GG genotype. Both genetic and nongenetic factors affect tenofovir plasma concentrations. These factors should be considered when adjusting tenofovir dosage regimens to ensure the efficacy and safety of a drug. (This study has been registered at ClinicalTrials.gov under registration no. NCT01138241.).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25801567      PMCID: PMC4432150          DOI: 10.1128/AAC.04930-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

Authors:  Sonia Rodríguez-Nóvoa; Pablo Labarga; Antonio D'avolio; Pablo Barreiro; Marta Albalate; Eugenia Vispo; Carmen Solera; Marco Siccardi; Stefano Bonora; Giovanni Di Perri; Vincent Soriano
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

2.  Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters.

Authors:  Stefan V Vormfelde; Markus Schirmer; Yohannes Hagos; Mohammad R Toliat; Sabine Engelhardt; Ingolf Meineke; Gerhard Burckhardt; Peter Nürnberg; Jürgen Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

3.  Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

Authors:  Hassane Izzedine; Jean-Sebastien Hulot; Eric Villard; Catherine Goyenvalle; Stephanie Dominguez; Jade Ghosn; Marc Antoine Valantin; Philippe Lechat; And Gilbert Deray
Journal:  J Infect Dis       Date:  2006-10-26       Impact factor: 5.226

4.  Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.

Authors:  Brian P Kearney; Anita Mathias; Angelique Mittan; John Sayre; Ramin Ebrahimi; Andrew K Cheng
Journal:  J Acquir Immune Defic Syndr       Date:  2006-11-01       Impact factor: 3.731

5.  Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.

Authors:  Sonia Rodríguez-Nóvoa; Pablo Labarga; Vincent Soriano; Deirdre Egan; Marta Albalater; Judit Morello; Lorena Cuenca; Gema González-Pardo; Saye Khoo; David Back; Andrew Owen
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

Review 6.  Pharmacogenetics of tenofovir treatment.

Authors:  Sonia Rodriguez-Novoa; Pablo Labarga; Vincent Soriano
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

7.  The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

Authors:  J J Kiser; M L Carten; C L Aquilante; P L Anderson; P Wolfe; T M King; T Delahunty; L R Bushman; C V Fletcher
Journal:  Clin Pharmacol Ther       Date:  2007-06-27       Impact factor: 6.875

8.  Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

Authors:  Leah Tong; Truc K Phan; Kelly L Robinson; Darius Babusis; Robert Strab; Siddhartha Bhoopathy; Ismael J Hidalgo; Gerald R Rhodes; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

9.  Population pharmacokinetics of tenofovir in AIDS patients.

Authors:  Marie-Claude Gagnieu; Mirna El Barkil; Jean-Michel Livrozet; Laurent Cotte; Patrick Miailhes; André Boibieux; Jérôme Guitton; Michel Tod
Journal:  J Clin Pharmacol       Date:  2008-09-08       Impact factor: 3.126

10.  Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.

Authors:  Jennifer J Kiser; Christina L Aquilante; Peter L Anderson; Tracy M King; Monica L Carten; Courtney V Fletcher
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

View more
  13 in total

Review 1.  Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.

Authors:  Andrea Calcagno; Jessica Cusato; Antonio D'Avolio; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

2.  Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11.

Authors:  Wisith Tun-Yhong; Chatchai Chinpaisal; Perayot Pamonsinlapatham; Sindchai Kaewkitichai
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs.

Authors:  Mengbi Yang; Xin Xu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2022-09-09       Impact factor: 4.936

Review 4.  Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.

Authors:  Nomusa M Zondo; Parveen Sobia; Aida Sivro; Sinaye Ngcapu; Veron Ramsuran; Derseree Archary
Journal:  Front Genet       Date:  2022-09-29       Impact factor: 4.772

5.  Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.

Authors:  Elodie Valade; Naïm Bouazza; Gabrielle Lui; Silvia M Illamola; Sihem Benaboud; Jean-Marc Treluyer; Aurélie Cobat; Frantz Foissac; Maïlys De Sousa Mendes; Camille Chenevier-Gobeaux; Marie Suzan-Monti; Christine Rouzioux; Lambert Assoumou; Jean-Paul Viard; Saïk Urien; Jade Ghosn; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

6.  ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment.

Authors:  Stefania Cheli; Sara Baldelli; Annalisa De Silvestri; Marta Fusi; Davide Minisci; Cristina Gervasoni; Dario Cattaneo; Emilio Clementi; Paola Meraviglia; Cristina Montrasio
Journal:  Pharmacogenomics J       Date:  2021-04-13       Impact factor: 3.550

Review 7.  Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes.

Authors:  Willy Albert Flegel; Kshitij Srivastava; Tristan Michael Sissung; Barry Ronald Goldspiel; William Douglas Figg
Journal:  Vox Sang       Date:  2020-09-30       Impact factor: 2.996

8.  Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.

Authors:  S E Salvaggio; A Giacomelli; F S Falvella; M L Oreni; P Meraviglia; C Atzori; E G I Clementi; M Galli; S Rusconi
Journal:  BMC Infect Dis       Date:  2017-06-05       Impact factor: 3.090

9.  Plasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort study.

Authors:  Yusuke Kunimoto; Hiroshi Ikeda; Satoshi Fujii; Manabu Kitagawa; Kieko Yamazaki; Hiromasa Nakata; Norimasa Noda; Tadao Ishida; Atsushi Miyamoto
Journal:  J Pharm Health Care Sci       Date:  2016-09-22

10.  Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging?

Authors:  Jingxian Chen; Farida S Akhtari; Michael J Wagner; Oscar Suzuki; Tim Wiltshire; Alison A Motsinger-Reif; Julie B Dumond
Journal:  Clin Transl Sci       Date:  2017-12-03       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.